Elanco Animal Health Inc (ELAN) shares surged 5.24% in pre-market trading on Wednesday following the release of its impressive first-quarter 2025 results and an upward revision of its full-year revenue guidance. The animal health company demonstrated robust performance across key financial metrics, surpassing analyst expectations.
Elanco reported adjusted earnings per share of $0.37 for Q1, significantly beating the analyst consensus estimate of $0.31 and marking a 8.82% increase from the same period last year. The company's quarterly revenue of $1.19 billion also exceeded expectations, coming in above the projected $1.17 billion. Notably, Elanco's adjusted EBITDA reached $276 million, well above the estimated $249.2 million, while adjusted net income stood at $184 million, surpassing the expected $153.7 million.
In light of its strong performance, Elanco raised its 2025 revenue guidance to a range of $4.51 billion to $4.58 billion, up from the previous forecast of $4.45 billion to $4.51 billion. The company maintained its 2025 adjusted earnings guidance at $0.80 to $0.86 per share. Additionally, Elanco increased its 2025 innovation revenue target to between $660 million and $740 million, further boosting investor confidence in the company's growth prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.